Study finds Abbott Laboratories' ABT-737 increases therapy effectiveness.

Massive sale of diagnostics business too good to be true?

Gene silencing by small interfering RNAs (siRNAs) has emerged as an extremely useful technology for discovery biology, but off-target activity has proved a stumbling block. Detailed mechanistic insights and chemical modification of siRNAs can now improve the robustness of RNAi experiments, as Kate McDonald reports.

Peptech chairman Mel Bridges today told shareholders that the company's best strategy for building value was to develop its product pipeline.

John Chiplin, the new CEO of Sydney biopharma Peptech (ASX:PTD), sees strong similarities between the state of Australia's biotechnology industry and California's nascent biotechnology industry in San Diego in the mid-1980s.

Anti-viral drug developer Narhex Life Sciences (ASX:NLS) has commenced recruitment of healthy volunteers for the phase I clinical trial of its anti-HIV protease inhibitor drug DG17.

Sydney antibody therapeutics developer Peptech (ASX:PTD) has signed an agreement with an unnamed biopharmaceuticals manufacturer to make its potent anti-inflammatory domain antibody (dAb) for preclinical and human clinical trials.

UK antibody therapeutics developer Domantis has pulled a double-headed rabbit out of the hat for its client, the big European pharma Abbott Laboratories.

Sydney peptide therapeutics developer Peptech (ASX:PTD) has reported "outstanding" results from a trial of an anti-TNF monoclonal antibody (mAb) resurrected from its tumour necrosis factor (TNF) research program of the late 1980s.

Agenix (OTC: AGXLY, ASX: AGX) subsidiary, Agen Biomedical has signed an agreement with diagnostics company Axis-Shield under which Axis-Shield will produce a new laboratory assay for deep vein thrombosis and pulmonary embolism. The Axis-Shield assay will use Agen's 3B6 D-dimer antibody, and will be incorporated into Abbott Laboratories' mmunodiagnostic analyser, AxSYM.

Starpharma (ASX: SPL, USOTC:SPHRY) has appointed former Cerylid Biosciences chief executive officer Dr Jackie Fairley to the newly created position of chief operating officer. Fairley will begin her role with Starpharma toward the middle of 2005.